JNJ - Johnson & Johnson
138.44 0.00 (0.00%)
After hours: 6:50PM EDT
| Previous Close | 137.17 |
| Open | 137.61 |
| Bid | 138.07 x 800 |
| Ask | 138.39 x 800 |
| Day's Range | 137.47 - 138.82 |
| 52 Week Range | 118.62 - 148.99 |
| Volume | 5,358,075 |
| Avg. Volume | 7,960,095 |
| Market Cap | 368.634B |
| Beta (3Y Monthly) | 0.66 |
| PE Ratio (TTM) | 24.69 |
| EPS (TTM) | 5.61 |
| Earnings Date | Apr 16, 2019 |
| Forward Dividend & Yield | 3.60 (2.62%) |
| Ex-Dividend Date | 2019-02-25 |
| 1y Target Est | 144.71 |
Market Realist•6 hours agoAnalysts Are Divided on Johnson & Johnson Stock
How Major Pharmaceutical Stocks Are Positioned This Month(Continued from Prior Part)Analysts’ recommendations and target priceWall Street analysts have given Johnson & Johnson (JNJ) a 12-month consensus target price of $144.71, 5.50% higher
- PR Newswire•10 hours ago
Johnson & Johnson to Host Investor Conference Call on First-Quarter Results
The webcast and presentation material are accessible at Johnson & Johnson's website www.investor.jnj.com. A replay of the webcast will be available approximately three hours after the conference call concludes.
- Zacks•yesterday
Johnson & Johnson (JNJ) Stock Sinks As Market Gains: What You Should Know
Johnson & Johnson (JNJ) closed the most recent trading day at $137.35, moving -0.19% from the previous trading session.
- InvestorPlace•yesterday
3 Consumer Staples Stocks to Trade in 2019
So far in 2019, the bulls have been in complete control over the stock market. This strength comes despite there not yet being a resolution to the global tariff war and while we await the conclusion of Brexit. However, when things go south for stocks the breakdown comes fast and portfolios suffer severe consequences if investors didn't balance them properly -- that brings us to consumer staples stocks.Some sectors are better at withstanding selling pressure than others. During a selloff, momentum stocks like Amazon (NASDAQ:AMZN) and Chipotle (NYSE:CMG) likely fall much faster than older, dividend-paying stocks. When times are tough, consumer stocks hold their value much better than most others.So why isn't everyone only in consumer staples stocks? Because what makes them almost bullet proof on the way down also slows them down during rallies. Traders are now on an upswing, so consumer stocks are generally lagging.InvestorPlace - Stock Market News, Stock Advice & Trading TipsBut therein lies the opportunity.This year, the Consumer Staples Select Sector SPDR ETF (NYSEARCA:XLP) is up only half as much as the S&P 500. So if the bulls remain in control for the next two weeks, consumer staple stocks will have the opportunity of a catch-up rally.Furthermore, they're worth snatching up because there are tremendous risks that still loom over the global business sentiment. Yes, stocks are rising now but most of the risks that caused the selling last year are still here. Only the threat from a combative U.S. Fed has abated. So if the sellers come back online, then the consumer staple investments will hold up better than the general markets, so they are a safer bet. * 10 Dividend Stock Winners These three consumer stocks stand out in the sector: Mondelez International (NASDAQ:MDLZ), Johnson & Johnson (NYSE:JNJ) and the Consumer Staples ETF (NYSEARCA:XLP). Here's more about each. Mondelez (MDLZ)Source: Shutterstock Mondelez made news last year as it invested $4 billion into Canopy Growth (NASDAQ:CGC), which quickly became a go-to cannabis stock to own (it had the best balance sheet of them all). So clearly, MDLZ is a company that is not afraid to take risks. And if the hype of the potential revenues from pot-related products and services is actually true, then MDLZ will get a handsome return on its investment.Meanwhile, MDLZ stock has its own reasons for ownership. It is now trading above the zone around $45.50, which has been resistance for years. So now it has solid footing below to attack the all-time highs. About a month ago it almost broke out of them, so it could be reloading to set new highs soon. If the geopolitical headlines comply, MDLZ stock should blaze a new trail soon. As long as it's above $45 per share, this is a real possibility.MDLZ sells at a price-to-earnings ratio of 25, which is in-line with the sector. So even though its management acts like it's a momentum company, the stock is not as frothy as one. Johnson & Johnson (JNJ)Source: Shutterstock Johnson & Johnson has been a proven performer for over a century, so the effects of last year's headline over the talcum lawsuits will inevitably fade. This is not to minimize the issue and its effects on those who suffered, but JNJ stock will recover from it. Owning JNJ stock now offers the opportunity to ride the snapback rally. * 7 Dividend Stocks to Buy Today JNJ is not screaming cheap, but the macroeconomic correction from last year and JNJ-specific headlines have shaken the weak hands from the stock. This makes for a strong base going forward. And the sellers will be less likely to panic at the first sign of weakness. Consumer Staples Select Sector SPDR ETFEven though buying the XLP is similar to investing individually in MDLZ or JNJ, doing so diffuses the risks of individual headlines. There are heavyweight tickers in the XLP, but none that would bring down the whole exchange-traded fund. They do, however, trade in unison, so that risk remains.But from here, the XLP chart looks bullish. Even though it is lagging the SPY in its bounce off the December lows, the XLP is setting higher lows and has a breakout neckline just above current levels. If the bulls can breakout of $55 per share they can overshoot to target the all-time highs from November. There will be resistance along the way, especially around $56 per share … this is where the real selling began last year.So why expect a move now?The XLP chart has set higher lows and lower highs, thereby bringing it to a point. These usually are precursors to big moves because the energy needs to disperse quickly. So if the stock market, in general, continues this breakout, the XLP will eventually finish its own breakout upwards.Nicolas Chahine is the managing director of SellSpreads.com. As of this writing, he did not hold a position in any of the aforementioned securities. You can follow him as @racernic on Twitter and Stocktwits. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 5 of the Best Stocks to Buy Under $10 * 7 Single-Digit P/E Stocks With Massive Upside * 7 Best Quantum Computing Stocks Trading Today Compare Brokers The post 3 Consumer Staples Stocks to Trade in 2019 appeared first on InvestorPlace.
- Insider Monkey•yesterday
Are Hedge Funds Right About Berkshire Hathaway Inc. (BRK-B)?
Reputable billionaire investors such as Jim Simons, Cliff Asness and David Loeb generate exorbitant profits for their wealthy accredited investors (a minimum of $1 million in investable assets would be required to invest in a hedge fund and most successful hedge funds won't accept your savings unless you commit at least $5 million) by pinpointing winning […]
- Investing.com•yesterday
UnitedHealth Shares Finding Their Mojo Again
Investing.com - UnitedHealth Group (NYSE:UNH) has been a big reason why the Dow has held its own lately.
- Zacks•yesterday
The Zacks Analyst Blog Highlights: Pfizer, Roche, Merck, Allergan and J&J
The Zacks Analyst Blog Highlights: Pfizer, Roche, Merck, Allergan and J&J
- Motley Fool•4 days ago
5 Recession-Proof Stocks
Almost no one is thinking about the fifth company, and therein lies opportunity.
- TheStreet.com•4 days ago
The Rally in Johnson & Johnson Looks Like it has Run Its Course
In Thursday night's Mad Money program, Jim Cramer told viewers that there are still plenty of opportunities for individuals to buy individual stocks. Cramer identified five risks that investors need to consider. In this Japanese candlestick chart of JNJ, below, we can see the price action of the last six months (only looking at six months of candles allows us to see the patterns better).
- Zacks•4 days ago
Pharma Stock Roundup: Regulatory Updates From MRK, PFE, J&J, AGN & Others
Regulatory updates from J&J (JNJ), Merck (MRK), Roche (RHHBY), Pfizer (PFE) and others.
- Zacks•5 days ago
J&J Seeks Approval for Darzalex in Expanded Patient Group
J&J (JNJ) files sBLA seeking approval for Darzalex combination regimen in newly- diagnosed, transplant ineligible multiple myeloma patient population.
Motley Fool•5 days agoJabil Circuit Inc (JBL) Q2 2019 Earnings Conference Call Transcript
JBL earnings call for the period ending February 28, 2019.
- TheStreet.com•5 days ago
The Perils of Stock Investing: Cramer's 'Mad Money' Recap (Thursday 3/14/19)
Making money in the stock market isn't easy, Jim Cramer admitted to his Mad Money viewers on the 14th anniversary of the show. For Thursday's session, Cramer identified five risks that investors need to consider.
- TheStreet.com•5 days ago
Jim Cramer: 5 Examples Show Why Stock Investing Is So Difficult
Consider these five, right in front of you on this one day, so you get the perils of stock ownership and know how to handle them when they occur.
- CNBC•5 days ago
Cramer: Five 'perils' of investing in individual stocks
Jim Cramer takes a look at some of the biggest headlines of the week that have rocked stocks on the market.
- Barrons.com•5 days ago
3 More Outstanding Funds for Dividend Investors
The Barron’s Income column has presented the five top-performing dividend ETFs and the five leading actively managed dividend mutual funds over the past five years. Here are three more strongly performing actively managed dividend funds.
- Reuters•5 days ago
US STOCKS-Wall St near flat as trade deal outlook uncertain
U.S. stocks were little changed in late afternoon trading on Thursday amid uncertainty over when a trade deal between the United States and China would be reached. President Donald Trump said the United States was doing very well in trade talks with China, but could not say whether a final deal would be reached. Trump and Chinese President Xi Jinping had been expected to hold a summit at the president's Mar-a-Lago property in Florida later this month, but no date has been set for a meeting.
- American City Business Journals•5 days ago
$18M Johnson & Johnson facility adds strength to Lake Nona's profile
Gloria Caulfield believes Johnson & Johnson will help boost the health of Lake Nona with the new $18 million headquarters of its Human Performance Institute. The vice president of strategic alliances for Lake Nona developer Tavistock Development Co. LLC said the new 31,500-square-foot Johnson & Johnson Human Performance Institute complex provides another reason for executives to be drawn to the area. The institute — which relocated from a smaller building farther north in Lake Nona — now has a larger space to teach and host participants in its classes providing lessons on how to prevent corporate burnout and more.
- Motley Fool•5 days ago
3 Penny Stocks That Could Make You Rich -- or Regretful
These three penny stocks have enormous upside potential, but they each come with a hefty dose of risk.
- InvestorPlace•5 days ago
Why Elite, Dividend-Paying Businesses Are the Ultimate “Wealth Defense”
If you're like a lot of folks, you're worried about inflation… and the danger it presents for people saving for retirement, or already in retirement.You might also be worried about another financial crisis wrecking your investments.If you're one of these people (and there's a good chance you are), the "no brainer" decision for you is to own elite, dividend-paying businesses.InvestorPlace - Stock Market News, Stock Advice & Trading TipsOwning an elite dividend-payer is a good inflation defense because its strong brand and loyal customer base will allow it to raise prices along with inflation. Its dividend will often increase at a faster rate of inflation, so the value of your income stream remains intact.These companies are safer, better places to park long-term wealth than any currency or any government bond. They are better for parking long-term wealth than gold.There are several major reasons why they're an incredible vehicle for your money…* For one, buying a great business is extremely cheap and easy. You don't get hit with big fees and commissions when you buy and sell them. You can't say that about real estate or art. Buying a great business through an online broker will cost you less than lunch at most restaurants.* Holding a great business is extremely cheap and easy. It's as easy as holding cash in the bank. There are no storage costs. There are no transportation costs. You don't have to get a safe-deposit box or a home safe, like you might do with gold or diamonds.* Shares of great businesses are liquid and freely traded. There's a huge market for these business. It's open most every business day.* Elite, dividend-paying businesses also pay out reliable, extremely safe income to their shareholders.* And finally, great businesses are great inflation-defense vehicles. They have long histories of rising in value when paper currencies decline in value.This is one of the most important aspects of these stocks…You see, governments have a long history of debasing currencies.When they want to pay for big social programs or wars, governments often print up extra currency units (like U.S. dollars). Every currency unit that is printed devalues the existing currency units. This is called "inflating" the money supply.Inflation is a way for governments to quietly clip small bits of value from your bank account and your wallet.Inflation is one of the greatest dangers a person saving for retirement faces. It can crush the future buying power of the money you save today.This is why owning great businesses is so important. Great businesses hold their value through inflationary periods.The world's most successful investor, Warren Buffett, figured this out a long time ago.Buffett urges people who are worried about paper-currency declines to own world-class businesses. He figured out a long time ago that owning great businesses is a better inflation defense than owning gold.I agree with Buffett on this point. The numbers prove it. Owning great businesses is better than gold when it comes to preserving and growing wealth over the long term.Consider that from the start of 1995 through early 2019 -- a time period that includes booms and busts for both stocks and gold - gold returned 241%.Now consider during that time…ExxonMobil (NYSE:XOM) returned 755%.Wal-Mart (NYSE:WMT) returned 1,007%.Johnson & Johnson (NYSE:JNJ) returned 1,257%.McDonald's (NYSE:MCD) returned 1,963%.(Note: These numbers factor in dividend reinvestment. Gold, of course, doesn't pay dividends at all.)Keep in mind… the companies I just mentioned were well-established enterprises in 1995. It wasn't like you were buying speculative startups.The numbers are clear. Owning elite businesses that generate consistent dividends is a better long-term strategy than owning gold.If you're concerned about inflation or another financial crisis, I encourage you to think about this idea… and how the world's greatest investor, Warren Buffett, approaches it.Sure… own some gold. Own some real estate. But keep in mind the proven wealth-building power of owning the world's best businesses.If you achieve great results with other strategies, congratulations. But if you're one of the many investors who has found lots of "action" -- but little success -- with exciting strategies, I hope you'll come around to the idea I've laid out for you today.Once you come around, and commit to a lifetime of accumulating elite, dividend-paying businesses purchased at reasonable prices, you'll eventually have a beautiful view of your "investment backyard"…At the end of your investment career, you'll have a large collection of elite, dividend-paying businesses… throwing off regular cash dividends.You'll have an orchard of money trees in your backyard.The branches of your money trees will be heavy with fruit every year. One "tree" will yield 20% on your original investment… one will yield 25% on your original investment… one will yield 30% on your original investment… and so on.Broad market corrections won't concern you. The latest government drama won't concern you.You'll sleep well at night knowing your elite businesses will continue to pay out regular cash dividends.You'll have a large and growing portfolio of the world's best soda companies, the world's best energy companies, the world's best food companies, etc.Instead of a fancy art collection or a car collection, you'll have a money tree collection.If you commit to a lifetime of accumulating elite, dividend-paying businesses purchased at reasonable prices, you're virtually guaranteed to build significant wealth in the stock market. And you will build that wealth safely.This is the world's 1 way to invest for retirement.It's the closest thing there is to having money trees growing in your back yard. Regards,BrianCompare Brokers The post Why Elite, Dividend-Paying Businesses Are the Ultimate aWealth Defensea appeared first on InvestorPlace.
- Reuters•5 days ago
US STOCKS-Wall Street muted on trade uncertainty, housing data disappoints
U.S. stocks flitted between gains and losses on Thursday as uncertainty over when a trade deal between the United States and China would be reached clouded sentiment. Wall Street's main indexes briefly moved higher after President Donald Trump said the United States was doing very well in trade talks with China, but could not say whether a final deal would be reached.
- CNBC•5 days ago
Johnson & Johnson shares slip after California jury orders it to pay $29 million in latest talcum cancer trial
J&J shares were lower after the company was ordered by a California jury to pay $29 million to a woman who alleged that asbestos in the company's talcum-powder-based products caused her cancer. J&J denies allegations that its talc causes cancer, saying numerous studies and tests by regulators worldwide have shown that its talc is safe and asbestos-free. Johnson & Johnson JNJ shares were down Thursday after the company was ordered by a California jury to pay $29 million to a woman who alleged that asbestos in the company's talcum-powder-based products caused her cancer.
- Barrons.com•5 days ago
J&J Takes Another Hit in Fight Against Asbestos Claims
Johnson & Johnson’s baby-powder problems continued Wednesday after a California jury decided the company must pay $29 million to a woman who claimed the company’s talcum powder-based products gave her cancer.
- Reuters•5 days ago
US STOCKS-Wall St dips on trade uncertainty, weak new home sales data
U.S. stocks dipped on Thursday weighed down by concerns of a delay in trade talks between the United States and China, and data which showed a higher-than-expected fall in new home sales in January. A meeting between President Donald Trump and China's Xi Jinping to sign an agreement to end their trade dispute was more likely to take place in April at the earliest, Bloomberg reported, a day after Trump said he was in no rush to complete a trade pact with China.
